NASDAQ:JBIO

Jade Biosciences Q1 2026 Earnings Results & Report

Jade Biosciences logo
$15.40 +0.06 (+0.39%)
Closing price 04:00 PM Eastern
Extended Trading
$15.44 +0.04 (+0.26%)
As of 06:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jade Biosciences missed analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.57 versus the -$0.52 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Jade Biosciences EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.52
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Jade Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jade Biosciences Q1 2026 Earnings FAQ

Jade Biosciences (NASDAQ:JBIO) reported earnings of -$0.57 per share for Q1 2026, missing the consensus estimate of -$0.52. The report was announced on Thursday, May 7, 2026.

Jade Biosciences Earnings Headlines

Jade Biosciences (JBIO) Stock Price Target 2026
Jade Biosciences (NASDAQ:JBIO) Upgraded at Wall Street Zen
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
See More Jade Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jade Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jade Biosciences and other key companies, straight to your email.

About Jade Biosciences

Jade Biosciences (NASDAQ:JBIO) is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease.

The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys.

Jade’s pipeline is focused on potential therapies for autoimmune conditions. The company’s work is at the drug-development stage, and its programs are intended to address diseases with significant unmet treatment needs.

View Jade Biosciences Profile